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resistance to biologicsDermatologists should be aware that autoantibody formation may occur after the initiation of biologic
therapy. This phenomenon has been referred to as immunogenicity and biologic fatigue. Because of this,
patients may experience loss of clinical efﬁcacy to a particular drug. To combat this phenomenon, low-
dose immunomodulators may be used in hopes of preventing autoantibodies. We review the current
literature and provide a basic treatment algorithm for patients with moderate to severe psoriasis.
© 2016 The Authors. Published by Elsevier Inc. on behalf of Women's Dermatologic Society. This is an open
access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).Introduction
Biologic agentsweremarketed to dermatologists as single drug ther-
apy, but when marketed to gastroenterologists and rheumatologists,
they were recommended as a supplement to other medications. Manu-
facturers eventually recognized that immunomodulators likemethotrex-
ate (MTX), azathioprine (AZA), andmercaptopurine (6-MP) reduced the
production of autoantibodies against tumor necrosis factor alpha (TNFα)
agents (Remicade, 2013). These data suggested that supplemental ther-
apy with immunomodulators might prolong the efﬁcacy of biologics
when compared to TNFαmonotherapy.
Biologics (with the exception of inﬂiximab) are fully human
monoclonal antibodies, so the immune response theoretically should
be quiescent (Scott and De Groot, 2010). However, the immune sys-
tem can unexpectedly produce anti-drug antibodies (ADA), resulting
in decreasing efﬁcacy of the biologics (Scott andDeGroot, 2010). This
effect was found among many biologics (the anti-TNFα agents
adalimumab, inﬂiximab and etanercept, and the anti-p40 [inter-
leukin 12/23] ustekinumab), and many patients have been placed
on an alternate biologic treatment regimen. The loss of efﬁcacy has
been partially attributed to neutralizing ADA formation against theer Inc. on behalf of Women'sbiologic drug. These ADA lead to the formation of drug-antibody
complexes that accelerate drug clearance from the circulation and
subsequently inhibit function (Carrascosa et al., 2014).
Several factors may contribute to immunogenicity, including
some that are extrinsic to the molecule (Scott and De Groot, 2010).
Intravenous administration favors immunogenic tolerance, while
subcutaneous or intramuscular injection favors a secondary immune
response to inﬂammation from the injection site and drainage to local
lymph nodes (Scott and De Groot, 2010). Antigen presenting cells
(dendritic cells) are abundant in the skin, but the patient’s human
leukocyte antigen type governs whether T-cell epitopes derived
from the biologic are presented to T cells (Scott and De Groot,
2010). Patients with psoriasis (PsO) may have an inherent T-cell de-
fect that increases immunity to a given drug; that is, the disease pro-
motes immunogenic responses to proteins that might not normally
trigger one (Scott and De Groot, 2010). A brief discussion regarding
the use of combining biologics and MTX for the treatment of Crohn’s
disease and rheumatoid arthritis (RA) are also provided.Methods
A systematic English-language literature search was conducted of
both PubMed and MEDLINE databases from inception through
December 10, 2014, to identify trials of biologics and MTX for the
treatment of PsO and psoriatic arthritis (PsA). Key search termsDermatologic Society. This is an open access article under the CC BY license
Table 1
Selected publications on combination therapy of biologics with MTX in PsO
Reference Study type Number of
patients
with
biologic and
MTX/mean
duratiof tx
weeks
Biologic and
average MTX
dose/other
systemic
agent
Timing of MTX Efﬁcacy Antibody Levels Tolerability
Lopez-Ferrer
et al. BrJ
Dermatol
2013; 169;
1141-7
Retrospective 26/24 Adalimumab
40mg eow
5±12.5mg
MTX/week2
Add-on MTX
when
insufﬁcient
response to
Adalimumab
After 24 weeks
Combination
group
73.5% PASI 75
67.5% PASI 90
Monotherapy
group
43.5% PASI 75;
34.8% PASI 90
Did not measure Infections, including de novo
infection by Mycobacterium
tuberculosis, accounted for most
SAEs, and paradoxical ﬂares of
psoriasis and psoriatic arthritis
were relatively frequent in daily
clinical practice.
Philipp et al. J
Dtsch
Dermatol
Ges 2012
10: 821-37
Retrospective 32/43 Adalimumab
40mg eow
12.4±4.5mg
MTX/week
20 patients
received MTX
concomitantly
85% PASI 50-751 Prevention of anti-ADA
antibodies was the reason in 3/
32 patients for combination
therapy with ADA and MTX.
Eighteen patients experienced
24 adverse events; none was
severe and/or required
hospitalization. More data are
needed to determine the long-
term safety and efﬁcacy of these
combinations
12 patients
received add
on MTX when
insufﬁcient
response to
Adalimumab
67% PASI 50-751
Van den Reek
et al. J
Dermatolog
Treat 2013;
24: 361-8
Prospective 11/24 Adalimumab
40mg eow
9.5±3.2mg
MTX/week
Add-on MTX
when
insufﬁcient
response to
adalimumab
After 12 weeks
9% PASI 50
After 24 weeks
18% PASI 50
Twenty-ﬁve percent of ﬁrst
treatment episodes with
adalimumab dose escalation
induced a PASI50 response after
12 weeks and 35% after 24
weeks. Addition of MTX to
adalimumab every other week
resulted in PASI50 in 9% after 12
weeks and 18% after 24 weeks.
No related serious adverse
events were reported.
Dalaker et al.
J Eur Acad
Dermatol
Venereol
2009; 23:
277-82
Retrospective 18/106 Inﬂiximab 3-
5mg/kg
11.66 mg
MTX/week2
MTX started
concomitantly
After 14 weeks
91.3% PASI 50
69.6% PASI 75
39.1% PASI 90
After 1 year
80% PASI 50
60% PASI 75
33.3% PASI 90
6-year-old boy, received
inﬂiximab 5 mg/kg instead of 3
mg/kg in combination with
methotrexate EXPRESS trial
with 5 mg/kg inﬂiximab
monotherapy with detectable
preinfusion serum inﬂiximab
concentrations: maintained
maintained their PASI 75
response over time; \
undetectable serum inﬂiximab
concentrations (below 0.1
g/mL), less likely to maintain
response. 5
Combination regimens of
inﬂiximab with methotrexate or
azathioprine were well tolerated,
and only one patient
discontinued therapy because of
an adverse event (lung
embolism) after two infusions
with inﬂiximab.
Driessen
et al. Br J
Dermatol
2008; 159:
460-3
Prospective 14/40 Etanercept
50mg twice
weekly the
ﬁrst 12 weeks,
than 25mg
twice tweekly
12.5mg2 MTX/
week
8 patients
started with
MTX and
received add-
on etanercept
Discontinuation of
MTX in 6 of these
patients resulted
in a decrease in
clinical efﬁcacy in
5 patients3
Did not measure Etanercept combined with
methotrexate was well tolerated,
and only mild adverse events
were reported.
6 patients
recived add-
on MTX when
insufﬁcient
response to
etanercept
67% improvement
efﬁcacy3
Zachariae
et al. Acta
Derm
Venereol
2008; 88:
495-501
Prospective 31/24 Etanercept
50mg twice
weekly the
ﬁrst 12 weeks,
than 25mg
twice weekly
13.4mg2 MTX/
week
Add-on
etanercept
when
insufﬁcient
response to
MTX
After 24 weeks
combination group
76.4% PASI 75
Did not measure Very little difference between
the two groups; The most
common organ system class
affected by adverse events was
infections, where 7 (25.0%) and
12 (38.7%) adverse events were
reported for the etanercept/
methotrexate taper and
combination groups,
respectively.
Etanercept
with MTX
tapered
treatment
Tapered MTX
group 51.3% PASI
75
Antoniou
et al. J Eur
Retrospective 11/24 Etanercept
50mg twice
MTX started
concomitantly
After 24 weeks Did not measure Etanercept was generally well
tolerated.
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Table 1 (continued)
Reference Study type Number of
patients
with
biologic and
MTX/mean
duratiof tx
weeks
Biologic and
average MTX
dose/other
systemic
agent
Timing of MTX Efﬁcacy Antibody Levels Tolerability
Acad
Dermatol
Venereol
2010; 24:
1413-20
weekly the
ﬁrst 12 weeks,
then 25 mg
twice weekly
15mg MTX/
week2
Combination
group
36.4% PASI 75
27.2% PASI 50
Monotherapy
group 41.7% PASI
75
8.3% PASI 50
Laboratory abnormalities
included hyperlipidaemia.
Discontinued in two patients as a
result of serious adverse events
that consisted of an oral
squamous cell carcinoma and a
diffuse B-cell-non-Hodgkin
lymphoma.
Gottlieb et al.
Br J
Dermatol
2012; 167:
649-57
Prospective 239/24 Etanercept
50mg twice
weekly the
ﬁrst 12 weeks,
then 25 mg
twice weekly
MTX ranging
from 7.5-
15mg/week
MTX started
concomitantly
After 12 weeks
Combination
group 70.2% PASI
75
Monotherapy
group 54.3% PASI
75
After 24 weeks
combination group
77.3% PASI 75
Monotherapy
group 60.3% PASI
75
Did not measure More patients in the
combination arm than in the
monotherapy arm experienced
at least 1 AE (74Æ9% vs. 59Æ8%),
but most AEs were mild or
moderate in severity.
Please note table has been reprinted with permission from publisher and van Bezooijen et al. (2015).
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asis”. Search terms were also used in combinations. The initial search
yielded 76 articles. Articles that did not mention treatment of the
disease, were not in English, and were not available online were ex-
cluded. After critical evaluation of the remaining articles by two in-
vestigators (C.B. and S.C.), we selected 18 articles to be included in
this manuscript.Results
Concomitant use ofMTXwith a biologic reduces immunogenicity.
Therefore, whenMTX or other immunosuppressant therapies are ad-
ministered in combination with biologic agents, the biologic has
more durable efﬁcacy. Key ﬁndings from selected PsO trial are sum-
marized in Table 1.Psoriasis and psoriatic arthritis
PsO is a chronic, inﬂammatory, T-cell-mediated autoimmune dis-
ease that results from activation of inﬂammatory cytokines (interfer-
on gamma, TNFα, IL-12, IL-23) and presents with erythematous scaly
plaques in 1% to 3% of Caucasians (Saraceno et al., 2009). Almost 40%
of psoriatic patients go on to develop PsA (Saraceno et al., 2009).Table 2
Half-life of Traditional Antipsoriatic Drugs
Drug Half-life
Methotrexate 3-10 hours (lower dose)
8-15 hours (higher dose)
Azathioprine 26-80 minutes (azathioprine)
3-5 hours (drug plus metabolites)
Acitretin 49 hours
Cyclosporine Variable (about 24 hours)
Hydroxyurea 3-4 hoursMTX is the most commonly used systemic treatment for
moderate-to-severe plaque PsO in Europe (Boffa, 2005; Mikuls and
O’Dell, 2000). It is thought to act as an immunosuppressant that tar-
gets lymphoid cell functions (Jeffes et al., 1995; Naldi and Grifﬁths,
2005; Schön and Boehncke, 2005) and reduces disease severity by
at least 50% (Boffa, 2005; Mikuls and O’Dell, 2000). However, side
effects include hematological malignancy, nonalcoholic fatty liver
disease, and lung disease. Careful monitoring of hepatic, renal, and
hematological labs is necessary, along with a liver biopsy if the total
cumulative dose reaches 1.5 g.
Despite MTX therapy, some patients may experience little to no
decrease in disease severity, warranting use of biologic therapies.
While biologics have revolutionized treatment for resistant PsO,
monotherapy with TNFα inhibitors may only be extremely effective
for a period of time. PsO patients may experience a diminished clini-
cal response as time progresses despite the same dosing schedule
(biologic fatigue). This subsequent decrease in effectiveness is due
to the development of ADA that may be prevented or reduced with
combination therapy.
Studies have demonstrated that combining adalimumab with
MTXcan reduce the formation of ADA(Bartelds et al., 2007; Pathirana
et al., 2009). Philipp et al. (2012) retrospectively studied patients
with psoriatic skin disease. All were given adalimumbab with anoth-
er systemic antipsoriatic drug and received on average 3.9
antipsoriatic therapies (phototherapy or systemic medications) be-
fore beginning combination therapy with adalimumab and a tradi-
tional systemic agent (Philipp et al., 2012). Combination therapy
with MTX was most common (n = 32), followed by acitretin (n =
4) and cyclosporine (CsA) (n = 3). Combination therapy was effec-
tive in the majority of patients: 30/39 (76.9 %) had an excellent
(n = 21) or good response (n = 9) (Philipp et al., 2012). This study
further substantiated the belief that the early combination of MTX
with adalimumab, and likely other biologics, could prevent immuno-
genicity in some patients (Philipp et al., 2012). Their retrospective
analysis revealed that combination therapy with adalimumab and
MTX prevented anti-adalimumab antibodies in 3/32 patients
Table 4
Route of administration and dosing schedule for biologics
Drug Route of
administration
Dosing schedule
Inﬂiximab Intravenous 5 mg/kg given as an IV induction regimen at 0,
2, and 6 weeks followed by a maintenance
regimen of 5 mg/kg every 8 weeks thereafter
Adalimumab Subcutaneously Initial dose of 80 mg, followed by 40 mg given
every other week starting one week after the
initial dose.
Etanercept Subcutaneously Initial: 50 mg subcutaneously twice weekly
(administered 3 to 4 days apart) for 3 months.
Alternatively, starting doses of 25 mg to
50 mg per week have been shown to be
effective.
Maintenance: 50 mg subcutaneously once
weekly.
Ustekinumab Subcutaneously 100 kg or less: Initial dose: 45 mg
subcutaneously once initially and 4 weeks
later
Maintenance dose: 45 mg subcutaneously
once every 12 weeks
Greater than 100 kg: Initial dose: 90 mg
subcutaneously once initially and 4 weeks
later
Maintenance dose: 90 mg subcutaneously
once every 12 weeks
Secukinumab Subcutaneously Recommended dosage is 300 mg by
subcutaneous injection at weeks 0, 1, 2, 3, and
4 followed by 300 mg every 4 weeks. For
some patients, a dose of 150 mg may be
acceptable.
⁎Efalizumab Subcutaneously 150 mg subcutaneously once a week
⁎ No longer on the market, voluntarily pulled by Genentech due to increased risk of
JC polyomavirus (1 in 500).
Table 3
Half-life of Biologics Used for PsO
Drug Half-life
Inﬂiximab 8-10 days
Adalimumab 10-20 days
Etanercept 3-5.5 days
Ustekinumab 15-32 days (average 3 weeks)
⁎Efalizumab 5 days
⁎ No longer on the market, voluntarily pulled by Genentech due to increased risk of
JC polyomavirus (1 in 500).
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effective in 17/20 patients; treatment was either started with
adalimumab and MTX simultaneously or adalimumab was added
after MTX therapy had already begun. In patients who did not re-
spond adequately to adalimumab alone, the addition of MTX led to
a good or very good response (8/12 patients). The study also revealed
a good safety proﬁle, with no adverse events (AEs) severe enough to
require hospitalization (Philipp et al., 2012). Themost commonly re-
ported side effects were upper respiratory tract infection (n = 5),
bronchitis (n = 2), and inﬂuenza (n = 1) (Philipp et al., 2012).
CsA is another immunosuppressant that induces double strands
breaks in DNA andmay be associatedwith an increased risk of malig-
nancies (Patel et al., 2009). Consequently, combination CsA and
adalimumab therapy should be reserved for temporary rescue therapy
or for severe recalcitrant pustular PsO. Although no large studies on
combination therapy with CsA and adalimumab in PsO patients are
available, case reports, case series, and open studies on patients with
PsO/PsA have been documented with etanercept (D'Angelo et al.,
2010; Kress, 2006; Lee et al., 2010; Yamauchi and Lowe, 2006). In
these reports, combination therapy consisting of etanercept and CsA
was effective and did not lead to serious AEs (D'Angelo et al., 2010;
Kress, 2006; Lee et al., 2010; Yamauchi and Lowe, 2006). Further stud-
ies on the synergistic effects of CsA and TNF antagonists are needed.
Acitretin is a second-generation, systemic retinoidwith no immu-
nosuppressive effects (Lee and Koo, 2005). Acitretin is safe for long-
term use and has no time limit restrictions, which makes it useful
for combination and maintenance therapy (Lee and Koo, 2005).
Three out of four patients who received combination therapy with
adalimumab and acitretin in case series by Philipp et al. (2012) had
a favorable response. Two previous reports of combination therapy
with ADA and acitretin also demonstrated tolerability and efﬁcacy
(Conley et al., 2006; Smith et al., 2008). In addition, a clinical study
of etanercept 25 mg/weekly combined with acitretin 0.4 mg/kg of
body weight daily found this regimen to be just as effective as
etanercept 25 mg twice weekly and more effective than acitretin
monotherapy (Gisondi et al., 2008). All of these ﬁndings suggest
that a combination of adalimumab and traditional systemic anti-
PsO treatments, especiallyMTX and acitretin, are promisingmethods
for managing severe or recalcitrant PsO.
In another study by Dalaker and Bonesrønning (2009), the effec-
tiveness of inﬂiximab in combinationwithMTXorAZAwas evaluated
for moderate-to-severe PsO. All patients had previously failed treat-
ment with MTX and ultraviolet B phototherapy. Thirteen of 23
patients had tried biologic agents other than inﬂiximab (12
etanercept, 7 efalizumab, 5 both etanercept and efalizumab, and 1
adalimumab). A 3-week washout period was done for all patients re-
ceiving another biological agent before inﬂiximab was administered.
Interestingly, one patient, a 6-year-old boy, safely received inﬂiximab
5 mg/kg instead of 3 mg/kg in combination with MTX as advised by
his pediatrician to reduce the risk of developing antibodies against
inﬂiximab during therapy (Dalaker and Bonesrønning, 2009).
Five patients who did not tolerate MTX were given AZA 50 mg/day
in combination with inﬂiximab 5 mg/kg, a regimen used for treatingCrohn’s disease. Treatment with AZA and inﬂiximab was initiated
simultaneously.
Patient data was available for a minimum of 4 weeks and up to 5
years and 5 months. Only two patients stopped inﬂiximab therapy
secondary to loss of response after 14months and 3 years, respective-
ly. Bothwere receiving inﬂiximabwithMTX. At week 14, 91.3% of pa-
tients achieved psoriasis area score index (PASI) 50, 69.6% achieved
PASI 75, and 39.1% achieved PASI 90 (Dalaker and Bonesrønning,
2009). There was a slight drop in efﬁcacy after 1 year, but the overall
effect of combination therapy was better than in studies with stan-
dard monotherapy (Menter et al., 2007; Reich et al., 2005). During
maintenance therapy, the approach to loss of effectiveness was to
shorten treatment intervals and/or increase the dose of MTX. The au-
thors aimed to use the lowest effective dose of both MTX and
inﬂiximab, as therapy is generally long term. This approach main-
tained efﬁcacy and was well tolerated, supporting the supplementa-
tion of biologics with low dose MTX (Eklund et al., 2003).
Inﬂiximab is a chimeric antibody that can promote formation of
neutralizing antibodies that may interfere with safety and efﬁcacy of
the drug. Formation of antibodies is associated with infusion reactions,
lower postinfusion inﬂiximab serum levels, and a shortened duration
of response (Maini et al., 1998; Rutgeerts et al., 2006). Concomitant
use of immunosuppressants (MTX, AZA) reduces the formation of an-
tibodies against inﬂiximab and improves the pharmacokinetics of the
drug, to enhance clinical efﬁcacy. Although MTX and AZA may be
equally effective in enhancing efﬁcacy, additional studies must be per-
formed to draw further conclusions (Rutgeerts et al., 2006).
ADAwere observed in 20 to 36% of psoriatic patients treated with
inﬂiximab 5 mg/kg every 8 weeks for 1 year in a large multicenter
trial (Remicade, 2013). In another study by Adişen et al. (2010),
mechanisms responsible for loss of clinical efﬁcacy to inﬂiximab
were studied. The murine binding portion that comprises 25% of the
antibody is antigenic in inﬂiximab and is believed to cause
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2005). To determine causation, peripheral blood samples were col-
lected from patients prior to the study and then before each
inﬂiximab infusion. Antibodies to inﬂiximab (ATI) were found in 5
(33.3%) of 15 patients (Adişen et al., 2010). Each patient developed
ATI at a different time (the ﬁfth, sixth, seventh, 10th, and 13th infu-
sions, respectively) after receiving an initial induction region of
inﬂiximab at week 0, 2, and 6, inﬂiximab, and then every 8 weeks.
In ATI positive patients, more infusions were necessary to reduce
the mean PASI (5.9 ± 3.2 inﬂiximab infusions achieved a decrease
in the PASI score from a mean of 20.4 ± 8.3 to 5.3 ± 2.4 in ATI-
negative patients versus 23.3± 11 to 10± 4.9 after 9± 5.2 infusions
in ATI-positive patients) (Adişen et al., 2010). This ﬁnding showed
that a similar numbers of inﬂiximab infusions (p= .16) failed to sat-
isfactorily reduce the mean PASI scores of ATI-positive patients (p=
.1). Thus, the prevention of ATI is associatedwith a better clinical out-
come. PsO patients may increase the efﬁcacy of inﬂiximab by addingFig. 1. Basic treatment algorithm foMTX to their regimen, althoughmore studies must be performed be-
fore deﬁnitive conclusions can be drawn.
Regularly scheduled maintenance infusions after an induction
regimen or extending intervals between infusions may prolong
the efﬁcacy of inﬂiximab by generating immunological tolerance
(Maini et al., 1998; Nast et al., 2007; Rutgeerts et al., 2004; Sandborn,
2003). In concordance with this belief, Menter et al. (2007) found in-
creased ATI formation in as-needed regimens (41.5%) compared to
regularly administering inﬂiximab every 8 weeks (35.8%). Moreover,
induction regimen and maintenance therapy with 8-week intervals
have been found better than the addition of an immunomodulator
for preventing antibody formation (Cheifetz and Mayer, 2005).
Despite the promising results of inﬂiximab therapy, a patient’s med-
ical history may preclude the provider from prescribing this agent.
In another study of severe PsO in which etanercept monotherapy
was insufﬁcient, Driessen et al. (2008) studied the effect of combining
etanercept with conventional PsO treatments. Data were extractedr moderate to severe psoriasis.
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etanercept and MTX simultaneously for an indeﬁnite period during
follow-up. Introducing MTX after etanercept resulted in an improve-
ment of PsO in four of six patients (66.7%). Eight patients were on
MTX therapy before the start of etanercept, and ﬁve of six (83.3%) pa-
tients who discontinuedMTX experienced a decrease in PASI. The re-
sults further established the beneﬁts of combining etanercept and
MTX when etanercept monotherapy fails to produce an adequate
clinical outcome.
Inﬂiximab accounts for the majority of cases of hepatitis B virus
(HBV) reactivation and fulminant hepatitis, but rare cases of HBV re-
activation with etanercept have been reported (Vilarrasa and Puig,
2014). Inﬂiximab is a monoclonal antibody that neutralizes soluble
and membrane bound TNFα, while etanercept is a fusion protein
that only binds to soluble TNFα (Vilarrasa and Puig, 2014). Therefore,
it may be beneﬁcial to use etanercept instead of inﬂiximab when a
patient has a history of HBV. The use of etanercept has also been
shown to enable tapering of MTX dosewithout increasing liver toxic-
ity, infections, or myelosuppression in PsO patients (Yamauchi et al.,
2005).
Zachariae et al. (2008) evaluated combination therapy for plaque
PsO patients who previously failed MTX therapy. Patients with
PASI ≥8 and/or total body surface are N10% despite more than 3
months of MTX were randomized to either etanercept with MTX ta-
pered and discontinued (n = 28) or etanercept with continuous
MTX (n = 31). Patients received an average MTX dose of 13.7 mg
perweek. Signiﬁcantlymore patients had a Physicians' Global Assess-
ment of "clear"/"almost clear" in the combination group compared
with etanercept/MTX taper (66.7 vs. 37.0%; p= .025). Limiting fac-
tors for the study included a short duration of 24 weeks. The most
common adverse side effect was infection, which was consistent
with the ﬁndings of similar studies.
In another retrospective study by Antoniou et al. (2010), the se-
quential treatment of switching high-need PsO patients from
efalizumab to etanercept was studied in 35 patients over a 4.5-year
period. They evaluated the effectiveness and safety of etanercept as
a sequential treatment in patients previously treatedwith efalizumab
and different transition strategies from efalizumab to etanercept.
After 24 weeks of etanercept therapy, 57% of patients had a PASI re-
duction of 75%, suggesting that alternating between biological agents
is feasible. Three different approaches were utilized: etanercept in
combination with CsA as bridge therapy, etanercept in combination
with MTX as bridge therapy, or etanercept monotherapy
(Antoniou et al., 2010). Combination therapy was efﬁcacious in
all patients, including eight patients with rebound phenomenon
from efalizumab (Aksu et al., 2011; Antoniou et al., 2010;
Chainani-Wu et al., 2014). From the study, it seemed that mono-
therapy with etanercept was not sufﬁcient when transitioning
from efalizumab in high-need patients with severe worsening
or rebound PsO (Antoniou et al., 2010). In such patients, the com-
bination of etanercept with CsA or MTX was more effective. Al-
though efalizumab is no longer in use due to an increased risk
of developing human John Cunningham polyomavirus (JC
polyoma induced leukoencephalopathy), this study illustrates
important considerations one must take when switching be-
tween different classes of biologics (Antoniou et al., 2010;
Bellizzi et al., 2013).
Switching between different classes of biologics, including
TNF ?thyc=5?> inhibitors and ustekinumab, is increasingly
used, raising efﬁcacy and safety questions. The ﬁrst head-to-head
study of biologics compared high-dose etanercept or ustekinumab
(45 mg) in 903 patients with PsO. At week 12, 67.5% of
ustekinumab-treated patients achieved a PASI 75, compared
with 56.8% of etanercept-treated patients (Grifﬁths et al., 2010).
Moreover, trials studying the sequential treatment from onebiological agent to another may contribute to our understanding
for managing complicated cases.
In another study by Gottlieb et al. (2012), patients with moderate
to severe plaque PsO who had not failed prior MTX or TNF-inhibitor
therapy were evaluated.43 Patients received etanercept plus MTX or
etanercept monotherapy (etanercept 50 mg twice weekly for 12
weeks followed by 50 mg once weekly for 12 weeks). Patients were
randomized 1:1 to receive MTX (7.5-15 mg weekly) or placebo. The
primary endpoint was the proportion of patients achieving ≥75% im-
provement in PASI 75 at week 24.
PASI 75 was signiﬁcantly higher at week 24 for the combina-
tion therapy group compared with the monotherapy group
(77.3% vs. 60.3%; p b .0001) (Gottlieb et al., 2012). Other PASI im-
provement scores at week 12 (PASI 75, 70.2% vs. 54.3% [p = .01];
PASI 50, 92.4% vs. 83.8% [p = .01]; and PASI 90, 34.0% vs. 23.1%
[p = .03]) showed similar results as did week 24 PASI 50 (91.6%
vs. 84.6%; p = .01) and PASI 90 (53.8% vs. 34.2%; p = .01). Signif-
icantly more patients receiving combination therapy than mono-
therapy had static Physicians' Global Assessment of clear/almost
clear at week 12 (65.5% vs. 47.0%; p = .01) and week 24 (71.8%
vs. 54.3%; p = .01) (Gottlieb et al., 2012). AEs were reported in
74.9% and 59.8% of combination therapy andmonotherapy groups,
respectively; three serious AEs were reported in each arm. This
demonstrated that combination therapy with etanercept plus
MTX had acceptable tolerability and increased efﬁcacy compared
with etanercept monotherapy in patients with moderate to severe
PsO.
In PsA studies, patients whowere ATI positive had higher rates of
drug clearance, reduced efﬁcacy, and infusion reaction (Remicade,
2013). In another PsA study, 37% of 128 patients treated with anti-
TNFα drug developed autoantibodies (Bardazzi et al., 2014). Almost
half (48.48 %) of those who received inﬂiximab developed autoanti-
bodies (Bardazzi et al., 2014). Forty-ﬁve patients were switched to
one ormore additional TNF-α inhibitors, and 25 developed autoanti-
bodies (Bardazzi et al., 2014).
Crohn’s disease
In a systematic review of Crohn’s patients who received
inﬂiximab and immunomodulators (6-MP, AZA, MTX), a lower inci-
dence of ADA was found in the combination therapy cohort (10%
and 18%, respectively; p = .02) (Cassinotti and Travis, 2009). ATI
were more common following drug free intervals greater than 16
weeks (Cassinotti and Travis, 2009). ATI were also associated with a
12% absolute increase in infusion reactions, but there was no increase
in serious infusion reactions or serum sickness-like reactions
(Cassinotti and Travis, 2009). Across all studies, those receiving con-
comitant immunodulators (6-MP, AZA, MTX) had a signiﬁcantly
lower incidence of infusion reactions (3%, 38/1174) compared with
patients not receiving concomitant immunosuppressive therapy
(6%, 171/2666; p b .001) (Cassinotti and Travis, 2009). These ﬁndings
led the authors to conclude that reduced antibody formation was of
clinical beneﬁt.
Rheumatoid arthritis
The use of TNF antagonists in combination with MTX is approved
for multiple rheumatologic disorders (Humira, 2004). The largest
prospective studies supporting the effects of combiningMTXwith bi-
ologic therapy have been done for RA. Patients in Studies RA-I, RA-II,
and RA-III were tested at multiple time points for antibodies to
adalimumab (Humira, 2004). Approximately 5% (58/1062) of pa-
tients developed low-titer antibodies to adalimumab at least once
during the ﬁrst year of treatment. Patients treated with concomitant
MTX had a lower rate of antibody formation than those on
83C.M. Blattner et al. / International Journal of Women's Dermatology 2 (2016) 77–84adalimumabmonotherapy (1% vs. 12%) (Humira, 2004).Withmono-
therapy, patients receiving injections every other week were more
likely to develop autoantibodies than those receiving weekly dosing
(Humira, 2004).
In another study, anti-adalimumab antibodies were detected in
21/121 patients (17%) during 28 weeks of treatment (Bartelds et al.,
2007). The European League Against Rheumatism stated that nonre-
sponders had antibodies signiﬁcantly more often than good re-
sponders (34% vs. 5%; p = .032) (Bartelds et al., 2007). Patients
with antibodies showed less improvement in disease activity (mean
[SD] ΔDAS28, 0.65 [1.35]) than patients without antibodies (mean
[SD], ΔDAS28 1.70 [1.35]) (p= .001) (Bartelds et al., 2007). Patients
with antibodies during follow-up also had lower serum adalimumab
concentrations at 28 weeks than patients without antibodies (medi-
an 1.2 mg/l, range 0.0-5.6 vs. median 11.0 mg/l, range 2.0-33.0, re-
spectively; p = .001) (Bartelds et al., 2007). Good responders had
higher serumadalimumab concentrations thanmoderate responders
(p=.021) and nonresponders (p=.001) (Bartelds et al., 2007). Con-
comitant MTX use was lower in the group with anti-adalimumab an-
tibodies (52%) than in the groupwithout antibodies (84%) (p= .003)
(Bartelds et al., 2007).
With etanercept, antibodies to the TNFα receptor portion or other
protein components of the drug were detected at least once in the
sera of approximately 6% of adult patients with RA, PsA, ankylosing
spondylitis, or plaque PoS (Enbrel, 2013). All antibodies were non-
neutralizing, and as expected, the percentage of patients testing pos-
itive for autoantibodies increased as the duration of study was ex-
tended (Enbrel, 2013). However, no data were collected beyond
120 weeks (Enbrel, 2013).
The standard therapeutic regimen of inﬂiximab for RA is 3 mg/kg
in combination with MTX (Dalaker and Bonesrønning, 2009). Immu-
nosuppression and episodic treatment ATI were studied in the
ACCENT I trial (Hanauer et al., 2002). In patients receiving inﬂiximab
episodically, the rate of ATI development without immunosuppres-
sion was 38% compared with 16% in patients receiving immunomod-
ulators (MTX, AZA). This difference was statistically signiﬁcant (p b
.001), but with maintenance dosing, the rate of ATI development
was lower, and the effect of immunomodulatorswas less pronounced
(Hanauer et al., 2002). In the 5 mg/kg every 8 week group, 7% of pa-
tients receiving immunomodulators developed ATI compared with
11% of patients not receiving immunosuppressants and in the 10
mg/kg 8-week group, 4% compared with 8%, respectively. However,
the difference was not statistically signiﬁcant between the mainte-
nance groups and those receiving immunomodulators.
Reasons for combination therapy with biologics
Reasons for starting combination therapy include lack of efﬁcacy
to traditional treatments, disease severity, suppressing antibody for-
mation, or brieﬂy overlapping treatment methods when switching
therapies. When combination therapy is used from the beginning,
the decision should bemade based on severity of disease. Table 2 pre-
sents the half-life for traditional antipsoriatic drugs, and Table 3 re-
views the same for each biologic agent discussed in this review.
Table 4 provides the route of administration and dosing for each of
these biologics.
Biologic treatments are largely devoid of liver toxicity. TNFα
antagonists treatments have proven to be effective and safe
in patients with chronic hepatitis C virus infections and other
noninfectious chronic liver disorders, including alcoholic and nonal-
coholic liver diseases. However, in chronic HBV, anti-TNFα treat-
ments carry a high risk of HBV reactivation, especially inﬂiximab.
Anti-IL-12/23 treatments are also effective in patients with PsO,
but data regarding their safety in chronic hepatitis infections are
still limited.Conclusion
In summary, combination therapy with biologic and traditional
systemic antipsoriatic drugs or ultraviolet light therapy if MTX fails
to work is a treatment option for certain subgroups of PsO patients.
This includes patients who do not respond adequately to traditional
Ps0 therapies, those with severe PsO, and those with pustular or
palmoplantar PsO. Combination therapy with MTX should be used
to reduce the risk of developing ADA antibodies.
A basic treatment algorithm for patients with moderate PsO
should include the initiation of MTX for at least 12 weeks to demon-
strate response (Fig. 1). If MTX monotherapy is inadequate, then the
addition of a biologic can be considered. Dermatologists should dose
biologics without interruption and at intervals that make sense with
regard to drug half-life. Concomitant use ofMTX reduces immunoge-
nicity. When given with MTX, biologic agents invariably show in-
creased and more durable efﬁcacy even when MTX is ineffective as
monotherapy. A sensible practice is to add a biologic therapy to
MTX, not vice versa, as immunogenicity may be difﬁcult to reverse
once it has occurred.References
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